Ending Neglect: The Elimination of Tuberculosis in the United States

Questions? Call 800-624-6242

About | Ordering | New

LoginRegister

| Items in cart [0]

HARDBACK
price:$39.95
add to cart

Rights & Permissions

Free PDF Access

Free Resources

Related Titles

Ending Neglect: The Elimination of Tuberculosis in the United States (2000)
Institute of Medicine (IOM)

Citation Manager Export the bibliographic data for this book in your chosen format
Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web.
Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book.
Reference Finder Paste in your own text to find books that relate to your topic.

Citation Manager

. "Appendix F Approval Dates for Existing and Prospects for Development of New Antituberculosis Drugs and Vaccines." Ending Neglect: The Elimination of Tuberculosis in the United States. Washington, DC: The National Academies Press, 2000.

Please select a format:

Page
249


E-mail Share on facebook Facebook Share on delicious Delicious Share on stumbleupon Stumble Share on twitter Twitter More Sharing ServicesMore

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.

Page 249

1) Activity: mole for mole as active as INH

2) Orally active

3) Bactericidal

4) Active vs. nongrowing organisms (e.g., M. tuberculosis cultured under anaerobic conditions)

5) Now in initial stages of testing

Ribozyme Pharmaceuticals